Health Care · Biological Products, (No Diagnostic Substances)

TECX Tectonic Therapeutic, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 1681087110 filings
Russell 2000

TECX at a glance

Tectonic Therapeutic, Inc. (TECX, SEC CIK 1681087) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as October 28, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • As of September 30, 2026, 22 institutional investment managers tracked by SignalX reported holding Tectonic Therapeutic, Inc. (TECX) shares worth $76.0 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by McNamara Peter on September 30, 2026 of 536 shares at $23.04 per share.
  • In the last 90 days, TECX insiders reported 0 open-market purchases ($0) and 2 open-market sales ($14K) on Form 4, a net sale of $14K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Insiders · 90 days
0 buys · 2 sells
Net −$14K
13F holders
22 funds
$76.0M · −3 vs prior quarter
Latest 8-K
Nov 5, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, no product sales
  • Operating expenses $23.5M vs $21.9M YoY, operating loss $23.5M vs $21.9M
  • Best program: TX45 R&D $5.7M vs $6.0M, down $0.4M; highest spend: platform $8.4M vs $7.0M
  • Cash $234.7M at September 30; nine-month operating cash use $54.8M vs $45.6M
  • APEX topline results expected by January 2027; TERRA planned by year-end 2026 amid additional funding needs

Risk Factors

  • Newly added regulatory risk: September 2026 FDA Fast Track designation for TX2100 does not assure accelerated review or marketing approval
  • Most materially updated market risk: AstraZeneca discontinued AZD3427 in February 2026, while AZD5462 showed Phase 2 efficacy, heightening relaxin-pathway competition
  • Compliance risk: December 2025 BIOSECURE Act could restrict work with designated Chinese biotechnology companies, threatening TX45 supply
  • Operational risk: WuXi Biologics remains the sole TX45 supplier, exposing clinical timelines to manufacturing disruption
  • Financial risk: $234.7 million cash and cash equivalents as of September 30, 2026, expected to fund operations for at least 12 months

AI summary of the TECX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Third-quarter results for the period ended September 30, 2026 announced
  • General business update accompanying the quarterly financial release

Item EX-99.1: Item EX-99.1

  • Q3 2026 net loss $21.3M, or $1.08 per share, versus $19.0M and $1.02 in Q3 2025
  • Cash $234.7M, including approximately $22.3M ATM proceeds, supports runway into Q1 2029 under current assumptions
Filed Sep 29, 2026Full analysis →

Item 8.01: Other Events

  • Phase 1 TX2100 results favorable for safety, tolerability and pharmacokinetics
  • TX2100 targets hereditary hemorrhagic telangiectasia, expanding Tectonic’s clinical pipeline

Item EX-99.1: Item EX-99.1

  • Phase 1a TX2100 doses generally safe and tolerated across six cohorts in 48 healthy volunteers
  • No deaths, serious adverse events, or severe treatment-emergent adverse events; anti-drug antibody results pending
Filed Aug 6, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q2 2026 earnings update: net loss $22.3M versus $20.0M, with R&D expense rising to $18.0M
  • TX45 APEX Phase 2 enrollment complete: 191 patients, including 137 enriched CpcPH patients; topline results expected early Q1 2027

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 financial results for quarter ended June 30, 2026 announced
  • General business update accompanies earnings release

AI summaries of TECX 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for TECX

Don't miss the next TECX filing

  • Alerts as it files. A push when TECX files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut TECX, by share count.
  • Ask anything. An AI agent that reads every TECX filing and answers with sources.

TECX alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
REICIN ALISEMOct 26, 2026$2.38
REICIN ALISEMOct 26, 2026-
McNamara PeterSellSep 30, 2026$23.04
McNamara PeterFSep 25, 2026$23.67
Lochner DanielFSep 25, 2026$23.67
Ruddy Marcella K.FSep 25, 2026$23.67
Schwabish MarcFSep 25, 2026$23.67
REICIN ALISEFSep 25, 2026$23.67

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Operating Income$10.2M-$58.0M-$84.0M
Net Income--$58.0M-$74.2M
Balance Sheet
Total Assets$101.1M$152.9M$261.0M
Equity$94.7M$140.8M$251.3M
ROE--41.2%-29.5%
Per Share
EPS$0.27$-6.83$-4.05
Cash Flow
Operating CF-$63.2M-$59.1M-$60.1M
CapEx$8K$156K$208K

Source: XBRL data in Tectonic Therapeutic, Inc. (TECX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate TECX share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
TECX shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202622$76.0M
Q2 202625$195.7M
Q1 202623$167.5M
Q4 202519$120.5M
Q3 202517$86.0M
Q2 202518$99.7M
Q1 202515$72.6M
Q4 202412$100.7M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 151 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

TECX filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 5, 2026Analysis
8-KNov 5, 2026Analysis-
4Oct 28, 2026--
4Oct 2, 2026--
4Oct 2, 2026--
4Oct 2, 2026--
4Oct 2, 2026--
4Oct 2, 2026--
8-KSep 29, 2026Analysis-
4Sep 8, 2026--
4Sep 8, 2026--
4Sep 8, 2026--
4Sep 8, 2026--
4Sep 8, 2026--
4Aug 26, 2026--
4Aug 14, 2026--
8-KAug 6, 2026Analysis-
10-QAug 6, 2026Analysis
4Jul 1, 2026--
4Jun 23, 2026--
4Jun 12, 2026--
4Jun 10, 2026-
4Jun 10, 2026-
4Jun 10, 2026-
4Jun 10, 2026-

Related Health Care companies

All Health Care →

TECX SEC filings: frequently asked questions

Are TECX insiders buying or selling?

In the last 90 days, Tectonic Therapeutic, Inc. (TECX) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $13,920 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold TECX stock?

As of September 30, 2026, the largest Tectonic Therapeutic, Inc. (TECX) holders among the 13F filers tracked by SignalX were BlackRock ($20.0 million), Vanguard Capital Management LLC ($11.9 million), State Street Corp ($5.1 million), Raymond James Financial ($4.6 million), Citadel Advisors LLC ($4.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What did TECX report in its latest 8-K?

Tectonic Therapeutic, Inc. (TECX) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Third-quarter results for the period ended September 30, 2026 announced.

What are the latest TECX SEC filings?

Tectonic Therapeutic, Inc. (TECX) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on October 28, 2026.

What is TECX's SEC CIK number?

Tectonic Therapeutic, Inc. (TECX)'s SEC Central Index Key (CIK) is 1681087. EDGAR lists every TECX filing under that number.

Ask anything about TECX

The research agent reads TECX's filings, financials, insider trades and 13F holders, then answers with sources.